On Feb. 24, 2025, the Food and Drug Administration ended the long-running federal monitoring program that had governed clozapine use for more than three decades. The program required clinicians and pharmacies to register and to log routine blood counts into a national database before dispensing subsequent supplies, a process designed to detect rare but serious drops in white blood cells. The FDA now recommends blood monitoring but no longer mandates enrollment in the registry, transferring the final responsibility for testing and ongoing assessment to clinicians and the informed choices of patients and families.
Clozapine is characterized in the source as the most effective antipsychotic for the sickest patients with schizophrenia. It is the only medication specifically approved for treatment-resistant schizophrenia, has evidence of reducing suicide risk, and is associated with lower mortality compared with alternative antipsychotics. Despite that profile, clozapine is strikingly underutilized: in the United States only about 4% of people with schizophrenia receive it, even though roughly one-third of patients might benefit.
Childhood-onset schizophrenia tends to be particularly treatment-resistant, meaning the population of young patients may stand to gain even more from access to clozapine. The author reports clinical trial and real-world experiences where clozapine produced rapid and sometimes dramatic clinical improvement in children who had been debilitated by relentless psychosis.
Although the registry created administrative hurdles — frequent early blood draws and mandatory database entries before pharmacies could release medication — the author argues the larger barrier was fear. Clozapine has a reputation for a long list of side effects and a rare but genuine risk of severe neutropenia. That reputation has made clinicians hesitant to prescribe it, often preferring to try multiple less-effective alternatives rather than initiate clozapine.
The FDA’s removal of the registry eliminates a bureaucratic obstacle, but it cannot by itself erase the concern clinicians feel about prescribing a drug with potentially serious adverse effects. The author describes how, early in his own experience, fear influenced his prescribing, but direct experience with the benefits and manageable monitoring rapidly reduced that fear.
In children, the risk of neutropenia appears to be higher than in adults, which amplifies clinician reluctance to start clozapine in pediatric patients. The author cites his inability to find a single child psychiatrist across four academic centers willing to initiate clozapine for a child with childhood-onset schizophrenia in a recent period. This clinical avoidance has real consequences: many children who might benefit remain untreated or receive a sequence of less-effective medications.
Families, the author reports, are often more ready than clinicians to consider clozapine. Parents who have tried multiple treatments and seen limited benefit often understand— and sometimes embrace—the risks when presented with the option of a potentially lifesaving therapy.
The author and colleagues have studied clozapine’s risks in children and published strategies to manage them. One cited approach is adding lithium to raise neutrophil counts sufficiently to permit continued clozapine treatment in some cases. The author notes that other side effects of clozapine can be managed and that there is an existing literature, including the author’s own group’s publications, detailing pediatric management approaches. He emphasizes that the problem with neutropenia is concentrated in the first months of treatment and, while not eliminated, can often be anticipated and navigated.
The FDA’s change is framed as an overdue alignment of regulation with clinical practice and evidence. By stopping the forced registry, the FDA acknowledged concerns raised by clinicians and advocates that a rigid, uniform monitoring program treated every patient as though the risk were constant and equivalent, when in practice the risk is front-loaded and variable.
Importantly, the FDA still recommends blood tests; it has simply shifted the locus of responsibility. Where the registry centralized monitoring decisions, responsibility now resides with clinicians’ judgment and patients’ informed consent. That shift creates an opportunity and a test: clinicians can use the flexibility to reach appropriate patients earlier, or fear can continue to limit clozapine use even without the bureaucratic barrier.
The author’s central appeal is that clinicians should not allow fear to dictate practice. Decades of treating clozapine only as a last resort are not supported by the scientific record according to the author; earlier use for those likely to benefit could reduce prolonged illness and premature death. The removal of the registry removes one stated reason clinicians have avoided clozapine, but it does nothing to change the need for careful monitoring, thoughtful risk mitigation, and clinician education.
Whether the FDA’s decision results in broader, earlier access to a proven, sometimes life-restoring therapy for children with severe, treatment-resistant psychosis depends on clinicians’ willingness to adopt evidence-based approaches, use available strategies to manage side effects, and engage patients and families in informed decision-making. The source frames this as both an opportunity and a responsibility that now rests more squarely with treating clinicians.